Robert F. Kennedy Jr., in his first time addressing HHS staffers as secretary, lays out his vision for the department. Read ...

Senate committee members heard arguments on a bill that would place a 10-year pause on administering mRNA vaccines in Idaho ...

Health care providers say that hesitation and outright resistance to vaccines have become disturbingly common even in ...

EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake ...

Penmenvy, which protects against five common types of disease-causing bacteria, is cleared for use in people aged 10 through ...

Moderna MRNA announced fourth-quarter 2024 results. Though earnings and sales beat estimates, both metrics declined ...

Thousands of U.S. health agency employees were terminated and told it was for poor performance, though they'd received strong ...

BofA analyst Tim Anderson lowered the firm’s price target on Moderna (MRNA) to $32 from $34 and keeps an Underperform rating on the shares.

We can refer to full-year 2019 revenue of about $51 billion and the company's comments about potential revenue of more than ...

For tech companies, the healthcare vertical is now the fastest growing business. The US, which spends about $5 trillion on ...

U.S. approves conditional use of avian influenza vaccine amid spreading outbreak U.S. greenlights temporary use of bird flu ...